publication date: Jun. 2, 2017
Issue 22 - Jun. 2, 2017
To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.
  • Flatiron compiles rich data on the uptake of PD-1 inhibitor drugs; A case study in real-world evidence?

    Utilization data compiled by Flatiron Health and made available to The Cancer Letter make it possible to visualize the dramatic uptake of immunotherapy drugs in the academic and community settings.

    The data illustrate nothing less than the real-time anatomy of the creation of a new standard of care in oncology. Charts, bars and tables published here first show these drugs emerge in the treatment of non-small cell lung cancer in early 2015 and rapidly build momentum.

  • Conversation with The Cancer Letter

    Cary Gross: We need to learn to analyze real-world evidence rigorously

    Cary Gross, professor of medicine and of epidemiology at Yale School of Medicine, has been working with a dataset of 35,000 non-small cell lung cancer patients, looking for signs of disparities in access to PD-1 checkpoint inhibitors.

    Working with data gathered by Flatiron Health, Gross has also been pondering the role real-world evidence can legitimately play in the development and approval of cancer drugs.

  • Conversation with The Cancer Letter

    A nascent group of academics plans to conduct randomized trials to determine value of care

    group of cancer researchers is trying to conducting randomized trials aimed at maximizing the value of oncology treatment regimens. 

    The group, called the Value in Cancer Care Consortium, is headed by Allen Lichter, former CEO of the American Society of Clinical Oncology.

  • MD Anderson posts four months of positive operating margins as deficit shrinks to $43.9 million

    MD Anderson Cancer Center reported positive operating margins after posting losses over the first four months of the fiscal year.

    Between September and December, the institution’s losses totaled $169.4 million, but between January and April, operating revenues added up to $125.5 million.

  • MD Anderson settles trademark litigation with Pelotonia, Soon-Shiong

    MD Anderson Cancer Center has settled two separate trademark suits protecting the Houston-based cancer center’s Moonshot program.

    One of the actions settled was filed against Pelotonia, a non-profit that coordinates a bike ride that raises money for The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard Solove Research Institute. MD Anderson claimed in a lawsuit that Pelotonia’s taglines “One Goal” and “One Goal: End Cancer” infringe the Houston cancer center’s trademark “One goal. Stop cancer” (The Cancer Letter, April 14).

  • In Brief

    • CancerLinQ partners with FDA to study real-world use of newly approved cancer treatments
    • NCCN and CancerLinQ collaborating to provide evidence-based, decision-making resources to physicians
    • First analysis of AACR Project GENIE data is published in Cancer Discovery
    • National Breast Cancer Coalition partners with DNA.Land to crowdsource large-scale breast cancer genomics database
    • Fred & Pamela Buffett Cancer Center is dedicated in Omaha
    • University of Pittsburgh Cancer Institute becomes UPMC Hillman Cancer Center
    • Markus Müschen named to The Norman and Sadie Lee Foundation Professorship in Pediatrics at COH
  • Drugs and Targets

    • Zykadia gets first-line ALK-positive metastatic NSCLC indication
    • Advaxis and BMS announce collaboration focused on metastatic cervical cancer
    • Johns Hopkins and Eisai extend drug collaboration

Copyright (c) 2017 The Cancer Letter Inc.